Related Experiment Video

Updated: Apr 1, 2026

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions
10:27

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions

Published on: October 21, 2022

2.1K

Circular RNAs in cancer: Its biogenesis, functions, relationships with cancer progression, applications in

Yusen Gao1, Lingling Xu2, Ruihua Sun3

  • 1School of Pharmacy, Fudan University, Shanghai, China.

Cancer Immunology, Immunotherapy : CII
|March 31, 2026
PubMed

Insights

Circular RNAs (circRNAs) are stable molecules regulating cancer progression and immunotherapy. This review explores their mechanisms, diagnostic potential, and therapeutic applications in oncology.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Circular RNAs (circRNAs) are unique RNA structures with high stability.
  • They are increasingly recognized for their roles in cancer development and progression.
  • Their involvement in the tumor immune microenvironment is a key area of research.

Purpose of the Study:

  • To systematically review circRNA biogenesis and functional mechanisms in cancer.
  • To explore the critical roles of circRNAs in cancer progression and immunotherapy.
  • To highlight circRNAs as potential noninvasive biomarkers and therapeutic targets.

Main Methods:

  • Literature review of circRNA research in cancer and immunotherapy.
  • Systematic summary of circRNA biogenesis and regulatory mechanisms.
  • Analysis of circRNA functions including miRNA sponging and protein interactions.

Main Results:

  • CircRNAs modulate key cancer hallmarks like metastasis, stemness, and chemoresistance.
  • They significantly impact cancer immunotherapy by influencing immune checkpoint blockade responses and cytokine secretion.
  • CircRNAs show promise as platforms for cancer vaccines and CAR-T cell therapy.

Conclusions:

  • CircRNAs are versatile regulators with significant potential in cancer diagnosis and therapy.
  • Their roles in modulating the tumor immune microenvironment offer novel immunotherapy strategies.
  • Despite challenges, circRNAs represent a promising frontier for advancing cancer treatment and diagnostics.
Keywords:
BiomarkersCAR-T therapyCancer immunotherapyCircRNAsImmune checkpoint blockadeTumor microenvironment

More Related Videos

Identification of Circular RNAs using RNA Sequencing08:25

Identification of Circular RNAs using RNA Sequencing

Published on: November 14, 2019

12.9K
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

505

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K